Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

NCT03964727 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

227

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Solid Tumor

Interventions

DRUG: Sacituzumab Govitecan-hziy

Sponsor

Gilead Sciences